Evidence map›Paper›PMID 27306615›Full record

Trial reportDiabetologia2016

Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment.

Paola Fioretto, Bergur V Stefansson, Eva Johnsson, Valerie A Cain, C David Sjöström

Abstract readLetterRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetologia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Review
  14. Article
  15. Article
  16. Article
  17. Comparative Efficacy of Novel Antidiabetic Drugs on Albuminuria Outcomes in Type 2 Diabetes: A Systematic Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2023
    Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Paola FiorettoClinica Medica 3, Department of Medicine, University of Padova, Via Giustiniani 2, 35128, Padova, Italy. paola.fioretto@unipd.it.
Bergur V StefanssonAstraZeneca, Gothenburg, Mölndal, Sweden.
Eva JohnssonAstraZeneca, Gothenburg, Mölndal, Sweden.
Valerie A CainAstraZeneca, Wilmington, Delaware, USA.
C David SjöströmAstraZeneca, Gothenburg, Mölndal, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AlbuminuriaBenzhydryl CompoundsDiabetes Mellitus, Type 2Diabetic NephropathiesFemaleGlomerular Filtration RateGlucosidesHumansMaleRenal Insufficiency, ChronicTreatment OutcomeBenzhydryl CompoundsdapagliflozinGlucosidesAlbuminuriaDapagliflozinRenal impairmentSGLT2 inhibitionType 2 diabetes

Identifiers

PMID27306615
PMCPMC4969341

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.